NCT01979601View on ClinicalTrials.gov

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Hypercholesterolemia
Interventions
DRUG

LGT209

150 mg lyophilized powder in glass vial

DRUG

Placebo

Placebo comparator

Trial Locations (2)

33169

Novartis Investigative Site, Miami Gardens

58104

Novartis Investigative Site, Fargo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY